President's Cancer Panel Recommendations and Responsible Stakeholders

Goals and Objectives	Responsible Stakeholder(s) and Other Entities
Goal 1: Reduce Missed Clinical Opportunities to Recommend and Administer HPV Vaccines	
Objective 1.1: CDC should develop, test, disseminate, and evaluate the impact of integrated, comprehensive communication strategies for physicians and other relevant health professionals.	Centers for Disease Control and Prevention
Objective 1.2: Providers should strongly encourage HPV vaccination of age-eligible males and females whenever other vaccines are administered.	Healthcare providers Health professionals organizations (e.g., American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, Society for Adolescent Health and Medicine)
Objective 1.3: Healthcare organizations and practices should use electronic office systems, including electronic health records (EHRs) and immunization information systems (IIS), to avoid missed opportunities for HPV vaccination.	Centers for Disease Control and Prevention Health professionals organizations (e.g., American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, Society for Adolescent Health and Medicine)
Objective 1.4: Healthcare payers should reimburse providers adequately for HPV vaccines and for vaccine administration and services.	Health insurance companies America's Health Insurance Plans Medicaid Healthcare organizations
Objective 1.5: The current Healthcare Effectiveness Data and Information Set (HEDIS) quality measure for HPV vaccination of adolescent females should be expanded to include males.	National Committee for Quality Assurance
Objective 1.6: Create a <i>Healthy People 2020</i> HPV vaccination goal for males.	U.S. Department of Health and Human Services
Goal 2: Increase Parents', Caregivers', and Adolescents' Acceptance of HPV Vaccines	
Objective 2.1: CDC should develop, test, and collaborate with partner organizations to deploy integrated, comprehensive communication strategies directed at parents and other caregivers, and also at adolescents.	Centers for Disease Control and Prevention

Goal 3: Maximize Access to HPV Vaccination Services	
Objective 3.1: Promote and facilitate HPV vaccination in venues outside the medical home.	State and local health departments State legislatures American Pharmacists Association
Objective 3.2: States should enact laws and implement policies that allow pharmacists to administer vaccines to adolescents, including younger adolescents.	State legislatures Health professionals organizations (e.g., American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, Society for Adolescent Health and Medicine) American Pharmacists Association
Objective 3.3: Overcome remaining barriers to paying for HPV vaccines, including payment for vaccines provided outside the medical home and by out-of-network or nonphysician providers.	Health insurance companies, health insurance exchanges America's Health Insurance Plans State insurance commissions
Goal 4: Promote Global HPV Vaccine Uptake	
Objective 4.1: The United States should continue its collaboration with and support of GAVI to facilitate HPV vaccine introduction and uptake in low-income countries.	The President Congress U.S. Department of Health and Human Services • Centers for Disease Control and Prevention • National Cancer Institute U.S. Agency for International Development
Objective 4.2: The United States should continue to support global efforts to develop comprehensive cancer control plans and cancer registries in low- and middle-income countries.	The President Congress U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Cancer Institute
High-Priority Research to Advance Prevention of HPV-Associated Cancers	
	 U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Institutes of Health Pharmaceutical and biotechnology companies Other public and private funders of biomedical research